Synlogic, Inc. (SYBX)
| Market Cap | 142.47M |
| Revenue (ttm) | 1.78M |
| Net Income (ttm) | -57.38M |
| Shares Out | 36.30M |
| EPS (ttm) | -1.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $4.08 |
| Previous Close | $4.09 |
| Change ($) | -0.02 |
| Change (%) | -0.37% |
| Day's Open | 4.11 |
| Day's Range | 3.98 - 4.14 |
| Day's Volume | 393,263 |
| 52-Week Range | 1.39 - 4.27 |
Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined s...
Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...
CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced t...
CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced t...
Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript
Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36...
CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported fi...
CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced ...
CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.
With a low capital cost and solid growth potential, many investors prefer to invest in penny stocks. Here are the top stocks to buy this year.
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc.
CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, tod...
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020. The event wil...
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, tod...
Synlogic: A Clinical-Stage Biopharma With A Good Risk/Reward Ratio
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2020 Results - Earnings Call Transcript
Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.
The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2019 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Synlogic.
With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...
As of late, it has definitely been a great time to be an investor Synlogic
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Shares of Synlogic Inc. SYBX, +4.77% sank 9.3% toward a record low in premarket trading Tuesday, after the biotechnology company said it has discontinued the development of SYNB1020 for the tr...
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2019 Results - Earnings Call Transcript
Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Synlogic (NASDAQ: SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.
Ginkgo Bioworks and Synlogic to collaborate on 'living medicine'
Bioengineers are reprogramming bacteria in our bodies to create living medicine.
Synlogic, Inc. announced a platform collaboration to speed up the development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform.
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2019 Results - Earnings Call Transcript
About SYBX
Synlogic, a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for ... [Read more...]
| Industry Biotechnology | |
| CEO Aoife Brennan | Employees 76 |
| Stock Exchange NASDAQ | Ticker Symbol SYBX |
Financial Performance
In 2019, Synlogic's revenue was $2.22 million, a decrease of -11.75% compared to the previous year's $2.52 million. Losses were -$51.37 million, 6.07% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 9.17, which is an increase of 125.03% from the latest price.